Syngene Expands Integrated Drug Development and Manufacturing Services with BMS
The collaboration between Syngene and Bristol Myers Squibb began in 1998, culminating in the establishment of the Biocon Bristol Myers Squibb Research and Development Center, Syngene's first dedicated R&D Center. The post Syngene Expands Integrated Drug Development and Manufacturing Services with BMS appeared first on GEN - Genetic Engineering and Biotechnology News .
Syngene International has extended its strategic partnership with pharmaceutical giant Bristol Myers Squibb (BMS) through 2035. The agreement broadens the scope of integrated services offered by Syngene, covering drug development from discovery to manufacturing, clinical trials, and IT services. Peter Bains, Syngene's managing director and CEO, emphasized the collaboration's foundation on scientific excellence, reliability, and a shared commitment to innovative therapies.
With this decade-long extension, Syngene and BMS can jointly plan for future growth and infrastructure development. For BMS, the partnership values patients and has been crucial in advancing their scientific goals, stated Payal Sheth, BMS's senior vice president for therapeutic discovery sciences. The collaboration began in 1998 and led to the creation of BBS Research and Development Center (BBRC) in 2009, which has become a significant strategic R&D site for BMS.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
